NewAmsterdam Pharma

US · NAMS #2583 by market cap Listed 1970

22.13 -0.14 -0.63%

Live - 5344 symbols - heartbeat 115s ago · 2026-10-08 07:56

Pre-market 21.97 -0.74%

After-hours 22.52 +1.76%

Overnight 22.09 -0.18%

Market cap: 2.65B
P/E (TTM): -10.25
P/B: 4.19
EPS: -1.72
Div yield: 0.00%
52W pos: 5%

Reader sentiment Are you bullish or bearish on NAMS?

Anonymous reader poll. Unscientific, not investment advice.

About NewAmsterdam Pharma

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Founded: 2022
CEO: Dr. Michael Harvey Davidson, M.D.
Employees: 100
Headquarters: Naarden, Noord-Holland, Netherlands (the)
Fiscal year end: 12-31
Website: newamsterdampharma.com

Company profile

Exchange: US
Symbol: NAMS
Market-cap rank: #2583
Listing date: 1970-01-01
Market cap: 2.65B
Float cap: 1.80B
Shares out: 119.54M
Float shares: 81.50M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:56:10 · For reference only, not investment advice and not tailored to your situation.